No Data
No Data
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
Global Market for Anti-Obesity Drugs Report, Featuring Altimmune, Currax Pharmaceuticals, Eli Lilly, F. Hoffmann-La Roche, Glaxosmithkline, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals and Vivus - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Market for Anti-obesity Drugs" report has been added to ResearchAndMarkets.com's offering.The report's scope includes an overview of the global market for anti-obe
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be
Altimmune to Present Clinical Data From Pemvidutide at Upcoming EASL International Liver Congress 2024
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of
No Data
104714243OP : Great assessment of this awesome potential